Manufacturer with High Purity and Stable Quality
Commercial Supply Favipiravir (CAS: 259793-96-9) and Related Intermediates:
Favipiravir CAS: 259793-96-9
3,6-Dichloropyrazine-2-Carbonitrile CAS: 356783-16-9
3,6-Difluoropyrazine-2-Carbonitrile CAS: 356783-28-3
6-Bromo-3-Hydroxypyrazine-2-Carboxamide CAS: 259793-88-9
3-Hydroxypyrazine-2-Carboxamide CAS: 55321-99-8
2-Aminopropanediamide CAS: 62009-47-6
Diethyl Aminomalonate Hydrochloride CAS: 13433-00-6
| Chemical Name |
Favipiravir |
| Synonyms |
T-705; 6-Fluoro-3-Hydroxy-2-Pyrazinecarboxamide |
| CAS Number |
259793-96-9 |
| CAT Number |
RF-API18 |
| Stock Status |
In Stock, Production Scale Up to Hundreds of Kilograms |
| Molecular Formula |
C5H4FN3O2 |
| Molecular Weight |
157.1 |
| Brand |
Ruifu Chemical |
| Item |
Specifications |
| Appearance |
Off-White Powder |
| Identification |
1) IR 2) HPLC |
| Melting Point |
188.0℃-193.0℃ |
| Related Substances
(Area Normalization) |
Any Single Impurity: ≤0.10% (HPLC) |
| Total Impurities: ≤1.0% (HPLC) |
| Purity / Analysis Method |
≥99.0% (HPLC) |
| Moisture (K.F) |
≤0.50% |
| Residue on Ignition |
≤0.10% |
| Heavy Metals |
≤20ppm |
| Residue Solvents |
|
| Methanol |
≤3000ppm |
| Ethyl Acetate |
≤5000ppm |
| Isopropanol |
≤5000ppm |
| Acetonitrile |
≤410ppm |
| n-Heptane |
≤5000ppm |
| Test Standard |
Enterprise Standard |
| Usage |
Active Pharmaceutical Ingredient (API); Treatment of COVID-19 |
Package: Bottle, Aluminum foil bag, 25kg/Cardboard drum, or according to customer's requirement.
Storage Condition: Store in sealed containers at cool and dry place; Protect from light, moisture and pest infestation.
Favipiravir (T-705) (CAS 259793-96-9) is one of the 5 compounds recommended by WHO for the investigation of treatment of COVID-19.
Favipiravir (T-705) is a selective inhibitor of viral RNA-dependent RNA polymerase with activity against many RNA viruses, influenza viruses, West Nile virus, yellow fever virus, foot-and-mouth disease virus as well as other flaviviruses, arenaviruses, bunyaviruses and alphaviruses. Favipiravir is a broad-spectrum antiviral drug that was cleared by the Drugs Controller General of India (DCGI) last week for “emergency restricted” use among Covid-19 patients. Favipiravir was originally developed in the late 1990s by a company that was later purchased by the Japanese firm Fujifilm as part of its transition from the photo business to healthcare. After being tested against a range of viruses, the drug was approved in Japan in 2014 for emergency use against flu epidemics or to treat new strains of influenza.